- Raw materials
- Hypnotics and sedatives
- Suvorexant
- Quality & compliance
- FDA-Approved
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Suvorexant API Manufacturers & Suppliers
4 verified results
All Suvorexant data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: >600
All certificates
Employees: 450+
All certificates
Employees: 25
All certificates
Employees: 10+
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Suvorexant | CAS No: 1030377-33-3 | GMP-certified suppliers
A medication that supports individuals with insomnia by helping improve sleep onset and maintenance, offered for reliable sourcing across major North American markets.
Therapeutic categories
Primary indications
- Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance
Product Snapshot
- Oral small‑molecule product supplied as film‑coated or coated tablets
- Used for management of insomnia related to sleep onset and sleep maintenance difficulties
- Approved in the United States and Canada, with additional investigational activity noted
Clinical Overview
Its therapeutic effect is mediated through selective dual antagonism of the OX1R and OX2R receptors. By preventing orexin A and orexin B from activating these receptors, suvorexant reduces signaling from wake-promoting neurons in the lateral hypothalamus. These neurons are physiologically active during wakefulness and cease firing during sleep. Inhibiting the orexin system decreases reinforcement of arousal networks, thereby facilitating sleep initiation and maintenance.
Suvorexant is administered orally and is primarily metabolized by CYP3A enzymes, consistent with its classification as a CYP3A substrate. Concomitant use with strong CYP3A inhibitors increases systemic exposure, while strong CYP3A inducers may reduce plasma concentrations. It is also characterized as a P-glycoprotein inhibitor, which may influence the disposition of co-administered substrates. The compound exhibits central nervous system activity consistent with its pharmacologic class, and residual sedation, next-day somnolence, and impaired driving performance are established safety considerations. Use at the lowest effective dose and caution in patients with compromised respiratory function are standard clinical safety practices.
Nonclinical data have identified dose-related central nervous system effects consistent with orexin blockade. Suvorexant is not recommended for individuals with narcolepsy due to the risk of exacerbating underlying orexin pathway dysfunction. Brand usage is most commonly associated with formulations used in major markets for chronic insomnia management.
For API procurement, emphasis should be placed on verifying stereochemical integrity, control of process-related impurities, and demonstration of compliance with regional regulatory specifications for hypnotic agents metabolized by CYP3A pathways.
Identification & chemistry
| Generic name | Suvorexant |
|---|---|
| Molecule type | Small molecule |
| CAS | 1030377-33-3 |
| UNII | 081L192FO9 |
| DrugBank ID | DB09034 |
Pharmacology
| Summary | Suvorexant is a dual antagonist of the orexin OX1R and OX2R receptors, blocking the actions of orexin A and B produced in the lateral hypothalamus. By reducing orexin‑mediated reinforcement of arousal pathways, it decreases wakefulness rather than directly inducing sleep. This modulation of arousal circuits supports its use in insomnia characterized by difficulty initiating or maintaining sleep. |
|---|---|
| Mechanism of action | Suvorexant is a dual antagonist of orexin receptors OX1R and OX2R. It exerts its pharmacological effect by inhibiting binding of neuropeptides orexin A and B, also known as hypocretin 1 and 2, that are produced by neurons in the lateral hypothalamus. These neurons control the wake-promoting centers of the brain and are active during wakefulness, especially during motor activities, and stop firing during sleep. By inhibiting the reinforcement of arousal systems, suvorexant use causes a decrease in arousal and wakefulness, rather than having a direct sleep-promoting effect. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Orexin receptor type 1 | Humans | antagonist |
| Orexin receptor type 2 | Humans | antagonist |
ADME / PK
| Absorption | Peak concentrations occur at a median Tmax of 2 hours under fasted conditions. Ingestion of suvorexant with a high-fat meal has no effect on AUC or Cmax, but may delay Tmax by approximately 1.5 hours. Mean absolute bioavailability of 10 mg is 82%. |
|---|---|
| Half-life | Mean half life is approximately 12 hours. |
| Protein binding | Suvorexant is extensively bound (>99%) to human plasma proteins and does not preferentially distribute into red blood cells. It binds to both human serum albumin and alpha1-acid glycoprotein. |
| Metabolism | Suvorexant is primarily metabolized by cytochrome-P450 3A4 enzyme (CYP3A4) with a minor contribution from CYP2C19. Major circulating metabolites are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active. There is potential for drug-drug interactions with drugs that inhibit or induce CYP3A4 activity. |
| Route of elimination | Approximately 66% is eliminated in feces and 23% is eliminated in urine. |
| Volume of distribution | Mean volume of distribution is approximately 49 litres. |
Formulation & handling
- Low aqueous solubility and moderate lipophilicity support conventional oral solid formulations, potentially benefiting from solubility‑enhancing excipients.
- As a small‑molecule solid API, it is generally stable under standard handling conditions, with typical precautions for moisture and light control.
- Oral use requires consideration of known grapefruit interactions due to CYP3A modulation, which may influence labeling and co‑administration guidance.
Regulatory status
| Lifecycle | Patent protection in the United States extends from 2029 through 2033, indicating the API remains in a mid‑to‑late patent‑protected phase. With current commercialization limited to the US and Canada, market maturity is moderate and shaped primarily by North American regulatory and competitive conditions. |
|---|
| Markets | US, Canada |
|---|
Supply Chain
| Supply chain summary | Suvorexant is supplied by a single originator company, with branded products marketed primarily in the United States and Canada and limited presence elsewhere. Current U.S. patents extend through 2029–2033, indicating that the molecule remains under active protection. These timelines suggest that broad generic competition has not yet emerged and is unlikely until closer to patent expiry. |
|---|
Safety
| Toxicity | Dose-related somnolence and CNS depression are the most common adverse effects associated with the use of suvorexant. It has also been shown to impair driving skills and may increase the risk of falling asleep while driving. Next-day impairments are found to be highest if suvorexant is taken with less than a full night of sleep remaining, with higher doses, or if co-administered with other CNS depressants or CYP3A inhibitors. Complex behaviours such as sleep driving, preparing and eating food, and making phone calls have been reported in association with the use of hypnotics such as suvorexant. A dose-dependant increase in suicidal ideation has been observed, especially in patients with a previous diagnosis of depression. Sleep paralysis, hypnagogic/hypnopompic hallucinations including vivid and disturbing perceptions, and mild cataplexy have also been reported. There are no adequate studies in pregnant women to ensure its safety during pregnancy or breast feeding. |
|---|
- CNS effects include dose‑related somnolence, psychomotor impairment, and complex sleep‑related behaviors
- Risk amplified by co‑administration with CNS depressants or CYP3A inhibitors
- Reports include next‑day residual sedation, sleep paralysis, hallucinations, and mild cataplexy, with dose‑dependent emergence of suicidal ideation in susceptible populations
Food & Drug Administration approved
The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments. FDA is important because it is intended to have companies produce their goods to certain standards and it presents this fact in a clear overview using FDA certificates. When a company is (US) FDA approved, it shows the American government has declared the API or medicine as safe and it can be sold, imported, or used in the United States. The USA is not the only country with a regulatory agency like FDA. Most other countries have agencies that are responsible for the national safety of pharmaceutical products. Some different kinds of organizations include:
EMA (European Medicines Agency, European Union)
MHRA (Medicines and Healthcare products Regulatory Agency, United Kingdom)
PMDA (Pharmaceuticals and Medical Devices Agency, Japan)
CDSCO (Central Drugs Standard Control Organization, India)
Suvorexant is a type of Hypnotics and sedatives
Hypnotics and sedatives belong to the pharmaceutical API category that plays a crucial role in the field of medicine. These compounds are specifically designed to induce sleep, reduce anxiety, and promote relaxation in patients. With their sedative properties, hypnotics and sedatives are commonly prescribed to treat sleep disorders, insomnia, and certain psychiatric conditions.
Pharmaceutical companies produce hypnotics and sedatives as active pharmaceutical ingredients (APIs), which are the key components responsible for the desired therapeutic effects. These APIs are carefully synthesized and formulated to ensure optimal efficacy and safety in patients. Common examples of hypnotics and sedatives include benzodiazepines, barbiturates, and non-benzodiazepine sedative-hypnotics.
The development of hypnotics and sedatives involves rigorous research and testing to ensure their effectiveness and minimize potential side effects. These APIs work by targeting specific receptors in the central nervous system (CNS), such as GABA receptors, which help regulate neuronal activity and promote sedation. By modulating these receptors, hypnotics and sedatives can produce a calming effect, induce sleep, and alleviate symptoms of anxiety and restlessness.
It is important to note that the use of hypnotics and sedatives should be carefully monitored by healthcare professionals, as they can have potential side effects, such as drowsiness, impaired coordination, and dependence. Additionally, these medications may interact with other drugs, necessitating caution and proper dosage adjustments.
In summary, hypnotics and sedatives are a vital category of pharmaceutical APIs used to promote sleep, reduce anxiety, and induce relaxation. Their precise mechanisms of action on the CNS receptors contribute to their therapeutic effects, making them valuable tools in managing sleep disorders and certain psychiatric conditions.
Suvorexant API manufacturers & distributors
Compare qualified Suvorexant API suppliers worldwide. We currently have 4 companies offering Suvorexant API, with manufacturing taking place in 2 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Apino Pharma Co., Ltd. | Producer | China | China | BSE/TSE, CoA, GMP, MSDS, USDMF | 229 products |
| Global Pharma Tek | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, ISO9001, MSDS | 484 products |
| Guangzhou Green Cross Pha... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS | 15 products |
| PharmaZell | Producer | Germany | India | CoA, FDA, GDP, GMP, MSDS, WC, WHO-GMP | 31 products |
When sending a request, specify which Suvorexant API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Suvorexant API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Suvorexant API
Sourcing
What matters most when sourcing GMP-grade Suvorexant?
Which documents are typically required when sourcing Suvorexant API?
Which manufacturers are known to produce Suvorexant API?
How can I request quotes for Suvorexant API from GMP suppliers?
Is a GMP audit report available for Suvorexant manufacturers?
How many suppliers offer Suvorexant API on Pharmaoffer?
Which countries are known to manufacture Suvorexant API?
Which certifications do suppliers of Suvorexant usually hold?
Technical
What is Suvorexant (CAS 1030377-33-3) used for?
Which therapeutic class does Suvorexant fall into?
What conditions is Suvorexant mainly prescribed for?
How does Suvorexant work?
What should someone know about the safety or toxicity profile of Suvorexant?
What are important formulation and handling considerations for Suvorexant as an API?
Is Suvorexant a small molecule?
Are there special stability concerns for oral Suvorexant?
Regulatory
Where is Suvorexant approved or in use globally?
What’s the regulatory and patent landscape for Suvorexant right now?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Suvorexant procurement?
Is Suvorexant included in the PRO Data Insights coverage?
Where can I access the API market report for Suvorexant?
